<DOC>
	<DOC>NCT00937664</DOC>
	<brief_summary>The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD7762 when given with the approved drug gemcitabine based on the side effects experienced by patients that receive both drugs.</brief_summary>
	<brief_title>Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Japanese patients with advanced solid tumors for which standard treatment does not exist or is no longer effective. Must be suitable for treatment with gemcitabine Relatively good overall health other than cancer Poor bone marrow function (not producing enough blood cells). Poor liver or kidney function. Serious heart conditions</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Phase I</keyword>
	<keyword>cancer</keyword>
	<keyword>solid tumors</keyword>
	<keyword>advanced solid malignancies</keyword>
	<keyword>dose escalation</keyword>
	<keyword>combination treatment</keyword>
	<keyword>CHK inhibitor</keyword>
	<keyword>Japanese</keyword>
</DOC>